Sign In
Buy PVCT
$0.0603
-0.0017 (-2.74%)
At Close: Jun 03, 2026
Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,
New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn. , May 04,
KNOXVILLE, Tenn., May 04, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biopharmaceutical company developing propri
KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will hold its 2026 Annual Meeting o
KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical r
Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 16,004.0% in December
01:40am, Tuesday, 13'th Jan 2026
Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 801,17
KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical r
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
08:00am, Monday, 29'th Sep 2025
KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lea
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
08:00am, Thursday, 26'th Jun 2025
KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by C
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
08:00am, Monday, 09'th Jun 2025
KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (th
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs
08:00am, Tuesday, 14'th Jan 2025
KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRo
Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript
05:10pm, Thursday, 14'th Nov 2024
Provectus Biopharmaceuticals, Inc. (OTC:PVCT) Q4 2024 Results Conference Call November 14, 2024 2:00 PM ET Company Participants Alyssa Barry - Co-Founder & Principal of Investor Relations, Alliance Ad
Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
08:00am, Thursday, 10'th Oct 2024
KNOXVILLE, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that it will host a conference call on Thurs
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Of
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
08:00am, Thursday, 07'th Mar 2024
KNOXVILLE, TN, March 07, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research on PV-10 (
